Literature DB >> 33868484

Analysis of radiotherapy-induced alteration of CD8+ T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma.

Yasumasa Mori1,2, Hiro Sato1, Takuya Kumazawa1, Tiara Bunga Mayang Permata3, Yuya Yoshimoto4, Kazutoshi Murata1, Shin-Ei Noda5, Takuya Kaminuma1, Ken Ando1, Takahiro Oike1, Noriyuki Okonogi6, Kohei Okada1, Sangeeta Kakoti1,7, Keiji Suzuki8, Hayato Ikota9, Hideaki Yokoo10, Takashi Nakano6, Tatsuya Ohno1, Atsushi Shibata7.   

Abstract

Radiotherapy induces an immune response in the cancer microenvironment that may influence clinical outcome. The present study aimed to analyse the alteration of CD8+ T-cell infiltration and programmed death-ligand 1 (PD-L1) expression following radiotherapy in clinical samples from patients with uterine cervical squamous cell carcinoma. Additionally, the current study sought to analyse the association between these immune responses and clinical outcomes. A total of 75 patients who received either definitive chemoradiotherapy or radiotherapy were retrospectively analyzed. CD8+ T-cell infiltration and PD-L1 expression were determined by immunohistochemistry using biopsy specimens before radiotherapy (pre-RT) and after 10 Gy radiotherapy (post-10 Gy). The PD-L1+ rate was significantly increased from 5% (4/75) pre-RT to 52% (39/75) post-10 Gy (P<0.01). Despite this increase in the PD-L1+ rate post-10 Gy, there was no significant association between both pre-RT and post-10 Gy and overall survival (OS), locoregional control (LC) and progression-free survival (PFS). On the other hand, the CD8+ T-cell infiltration density was significantly decreased for all patients (median, 23.1% pre-RT vs. 16.9% post-10 Gy; P=0.038); however, this tended to increase in patients treated with radiotherapy alone (median, 17.7% pre-RT vs. 24.0% post-10 Gy; P=0.400). Notably, patients with high CD8+ T-cell infiltration either pre-RT or post-10 Gy exhibited positive associations with OS, LC and PFS. Thus, the present analysis suggested that CD8+ T-cell infiltration may be a prognostic biomarker for patients with cervical cancer receiving radiotherapy. Furthermore, immune checkpoint inhibitors may be effective in patients who have received radiotherapy, since radiotherapy upregulated PD-L1 expression in cervical cancer specimens.
Copyright © 2021, Spandidos Publications.

Entities:  

Keywords:  CD8+ T cell; cervical cancer; immune modulation; programmed death-ligand 1; radiotherapy; tumor microenvironment

Year:  2021        PMID: 33868484      PMCID: PMC8045163          DOI: 10.3892/ol.2021.12707

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  39 in total

1.  Cervical cancer.

Authors:  Jayanthi S Lea; Ken Y Lin
Journal:  Obstet Gynecol Clin North Am       Date:  2012-04-24       Impact factor: 2.844

2.  The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.

Authors:  Ronan J Kelly; Ali H Zaidi; Matthew A Smith; Ashten N Omstead; Juliann E Kosovec; Daisuke Matsui; Samantha A Martin; Christina DiCarlo; E Day Werts; Jan F Silverman; David H Wang; Blair A Jobe
Journal:  Ann Surg       Date:  2018-12       Impact factor: 12.969

3.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Authors:  P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

4.  Expression of programmed death 1 ligands by murine T cells and APC.

Authors:  Tomohide Yamazaki; Hisaya Akiba; Hideyuki Iwai; Hironori Matsuda; Mami Aoki; Yuka Tanno; Tahiro Shin; Haruo Tsuchiya; Drew M Pardoll; Ko Okumura; Miyuki Azuma; Hideo Yagita
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

Review 5.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

6.  Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.

Authors:  Alina Sturdza; Richard Pötter; Lars Ulrik Fokdal; Christine Haie-Meder; Li Tee Tan; Renaud Mazeron; Primoz Petric; Barbara Šegedin; Ina Maria Jurgenliemk-Schulz; Christel Nomden; Charles Gillham; Orla McArdle; Erik Van Limbergen; Hilde Janssen; Peter Hoskin; Gerry Lowe; Ekkasit Tharavichitkul; Elena Villafranca; Umesh Mahantshetty; Petra Georg; Kathrin Kirchheiner; Christian Kirisits; Kari Tanderup; Jacob Christian Lindegaard
Journal:  Radiother Oncol       Date:  2016-04-29       Impact factor: 6.280

7.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.

Authors:  Xiaobin Gu; Meilian Dong; Zheyan Liu; Yin Mi; Jing Yang; Zhigang Zhang; Ke Liu; Li Jiang; Yue Zhang; Shiliang Dong; Yonggang Shi
Journal:  Cancer Cell Int       Date:  2019-05-23       Impact factor: 5.722

Review 10.  Radiation effects on antitumor immune responses: current perspectives and challenges.

Authors:  Thomas Walle; Rafael Martinez Monge; Adelheid Cerwenka; Daniel Ajona; Ignacio Melero; Fernando Lecanda
Journal:  Ther Adv Med Oncol       Date:  2018-01-18       Impact factor: 8.168

View more
  3 in total

Review 1.  T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker.

Authors:  Constantin N Baxevanis; Angelos D Gritzapis; Ioannis F Voutsas; Panagiota Batsaki; Maria Goulielmaki; Maria Adamaki; Vassilios Zoumpourlis; Sotirios P Fortis
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

Review 2.  Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy.

Authors:  Masanori Someya; Yuki Fukushima; Tomokazu Hasegawa; Takaaki Tsuchiya; Mio Kitagawa; Toshio Gocho; Shoh Mafune; Yutaro Ikeuchi; Yoh Kozuka; Yoshihiko Hirohashi; Toshihiko Torigoe; Masahiro Iwasaki; Motoki Matsuura; Tsuyoshi Saito; Koh-Ichi Sakata
Journal:  Jpn J Radiol       Date:  2022-01-01       Impact factor: 2.701

Review 3.  Value of carbon-ion radiotherapy for early stage non-small cell lung cancer.

Authors:  Hanguang Ruan; Juan Xiong
Journal:  Clin Transl Radiat Oncol       Date:  2022-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.